Cyclo Therapeutics Inc - Ordinary Shares - Class A
NASDAQ:CYTH 4:00:00 PM EDT
| Market Cap (Intraday) | 26.45M |
| Current PE | N/A |
| Forward PE | N/A |
| 2yr Forward PE | N/A |
| 10-Day MA | $1.51 |
| 50-Day MA | $1.54 |
| 200-Day MA | $1.43 |
Cyclo Therapeutics Inc - Ordinary Shares - Class A Stock, NASDAQ:CYTH
6714 NW 16th Street, Suite B, Gainesville, Florida 32653
United States of America
Phone: +1.386.418.8060
Number of Employees: 9
Description
Cyclo Therapeutics, Inc. engages in the development of cyclodextrin-based biopharmaceuticals for the treatment of disease. Its product pipeline include Trappsol Cyclo, which treats Neimann-Pick Type C disease and Alzheimer's disease. The company was founded by Charles E. Rick Strattan on August 9, 1990 and is headquartered in Gainesville, FL.